Information Provided By:
Fly News Breaks for November 17, 2016
ENZY
Nov 17, 2016 | 05:42 EDT
Wells Fargo analyst John Baumgartner downgraded Enzymotec to Market Perform following the company's Q3 earnings miss and reduced FY16 outlook. The stock's "deep value no longer outweighs the underperformance," Baumgartner tells investors in a research note. He lowered his price target range for the shares to $5-$6 from $11-$12.
News For ENZY From the Last 2 Days
There are no results for your query ENZY